The effect of remote ischaemic preconditioning on the immune response in healthy volunteers

A paired-analysis trial investigating the effect of remote ischaemic preconditioning compared with no remote ischaemic preconditioning on inflammatory cytokine production and leukocyte function in healthy volunteers

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000856910

Enrollment

Registered

2011-08-11

Start date

2011-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

There is evidence that remote ischaemic preconditioning (RIPC) protects organs from the effects of decreased blood supply during procedures such as heart surgery. Currently it is not known how this protection occurs, but it appears that RIPC may affect inflammation. This study will investigate the effects of RIPC on the immune system in healthy volunteers. The RIPC takes 30 minutes in total and involves inflation of a blood-pressure cuff on the upper arm for five minutes, temporarily preventing blood flow, followed by deflation for five minutes. This process is repeated three times. Participants will undergo a control session where a blood pressure cuff will be placed on the upper arm for 30 minutes without inflation. Seven days later a treatment session will take place where the blood pressure cuff is placed on the same arm and RIPC is performed. At each of these sessions samples of blood will be collected prior to placement of the blood pressure cuff, and at 20 minutes, 1 hour and 4 hours following. Blood will be analysed by looking for changes in immune cells and markers of inflammation.

Interventions

A blood pressure cuff will be placed on the non-dominant upper arm and inflated to 200 mmHg for five minutes, then deflated for five minutes. This cycle will be repeated three times, taking a total of thirty minutes.

Study design

Allocation

Non-randomised trial

Intervention model

Other

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers that have received a tetanus vaccine or booster within the last 10 years

Exclusion criteria

Peripheral vascular disease Smoking Regular use of medication Acute illness (within 1 week of the study visits)

Outcome results